J B Chemicals & Pharmaceuticals Ltd. - Research Center
506943 JBCHEPHARM Group (A) BSE data
Add to watchlist
| Results | |
| Statement |
Balance sheet
|
| More |
Balance sheet
(Rs crore)
| Mar ' 24 | Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | |
|---|---|---|---|---|---|
| Sources of funds | |||||
| Owner's fund | |||||
| Equity share capital | 15.52 | 15.48 | 15.46 | 15.46 | 15.46 |
| Share application money | - | 121.62 | 62.65 | - | - |
| Preference share capital | - | - | - | - | - |
| Reserves & surplus | 2,870.74 | 2,305.38 | 2,025.56 | 1,791.00 | 1,429.83 |
| Loan funds | |||||
| Secured loans | 341.80 | 526.93 | 26.32 | 26.43 | 32.04 |
| Unsecured loans | - | - | - | - | - |
| Total | 3,228.06 | 2,969.41 | 2,129.98 | 1,832.89 | 1,477.33 |
| Uses of funds | |||||
| Fixed assets | |||||
| Gross block | 2,595.81 | 2,444.24 | 1,773.44 | 1,097.48 | 1,094.50 |
| Less : revaluation reserve | - | - | - | - | - |
| Less : accumulated depreciation | 670.39 | 622.58 | 569.77 | 532.88 | 511.29 |
| Net block | 1,925.42 | 1,821.66 | 1,203.67 | 564.60 | 583.21 |
| Capital work-in-progress | 76.06 | 55.15 | 18.68 | 25.57 | 16.17 |
| Investments | 531.23 | 338.94 | 145.69 | 810.85 | 536.23 |
| Net current assets | |||||
| Current assets, loans & advances | 1,380.92 | 1,254.40 | 1,170.04 | 799.41 | 675.41 |
| Less : current liabilities & provisions | 685.58 | 500.74 | 408.08 | 367.54 | 333.69 |
| Total net current assets | 695.34 | 753.66 | 761.95 | 431.87 | 341.72 |
| Miscellaneous expenses not written | - | - | - | - | - |
| Total | 3,228.06 | 2,969.41 | 2,129.98 | 1,832.89 | 1,477.33 |
| Notes: | |||||
| Book value of unquoted investments | 166.58 | 146.75 | 145.69 | 145.88 | 145.85 |
| Market value of quoted investments | 364.65 | - | - | 664.97 | 390.38 |
| Contingent liabilities | 1,110.90 | 120.63 | 68.13 | 117.00 | 121.66 |
| Number of equity sharesoutstanding (Lacs) | 1551.95 | 773.78 | 772.82 | 772.82 | 772.82 |
© 2025 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis